Other
Total
Biogen Total increased by 10.4% to $1.37B in Q1 2026 compared to the prior quarter. Over 3 years (FY 2020 to FY 2025), Total shows a downward trend with a -15.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2016
Last reportedQ1 2026
How to read this metric
Changes reflect shifts in the cost basis of the investment portfolio due to purchasing or selling activity.
Detailed definition
The amortized cost basis of debt securities classified as available-for-sale, excluding primary categories. This represe...
Peer comparison
Commonly reported by insurers with large fixed-income portfolios.
Metric ID:
other_available_for_sale_debt_securities_amortized_cost_basisHistorical Data
12 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.22B | $2.38B | $2.44B | $3.02B | $3.28B | $2.12B | $2.20B | $3.13B | $4.69B | $97.60M | $1.24B | $1.37B |
| QoQ Change | — | +7.1% | +2.3% | +23.9% | +8.6% | -35.3% | +3.6% | +42.5% | +49.6% | -97.9% | >999% | +10.4% |
| YoY Change | — | — | — | — | +47.5% | -10.9% | -9.7% | +3.8% | +42.9% | — | — | — |
Range$97.60M – $4.69B
CAGR-16.2%
Avg YoY Growth+14.7%
Median YoY Growth+3.8%
Current Streak2 quarters growth
Total at Other Companies
Frequently Asked Questions
- What is Biogen's total?
- Biogen (BIIB) reported total of $1.37B in Q1 2026.
- What is the long-term trend for Biogen's total?
- Over 3 years (2020 to 2025), Biogen's total has grown at a -15.4% compound annual growth rate (CAGR), from $2.05B to $1.24B.
- What does total mean?
- The original cost of debt investments held for sale, adjusted for accounting amortization.